ESTRO35 Programme Book

09:35 > Future selection practice for proton therapy: selection of patients based on treatment planning comparison and NTCP-modelling Speaker: H. Langendijk (The Netherlands)

SP-0011

SATURDAY 30 APRIL 2016

Symposium MITIGATING NORMAL TISSUE TOXICITY 08:45 - 10:00 | LONDRA

The session is a well balanced session consisting of two biologically-oriented and experimental talks (by S. van der Veen and L. Meziani) and one clinically oriented (by S. Delanian). The first talk will show the benefit triggered by molecular modulation using ACE inhibitors on cardiopulmonary function and cardiac damage. The second will review the clinical benefit of the combination Pentoxifyllin, Vitamin E and Clodronate with possible mechanistic insights. The third will show the contribution of innate immune system to late radiation-induced pulmonary damages with a specific focus on macrophages

leading to innovative therapeutic intervention. Chair: M-C Vozenin (Switzerland) Co-Chair: L. Pirtoli (Italy)

08:45 > The use of ACE inhibitors to attenuate thoracic irradiation-induced cardiopulmonary toxicity. Speaker: S. Van der Veen (The Netherlands) 09:10 > Radiation-induced musculosqueletic late damages: possible clinical cure or simple mitigation? Speaker: S. Delanian (France) 09:35 > Radiation-induced lung fibrosis is associated with M2 interstitial and hybrid alveolar macrophages Speaker: L. Meziani (France)

SP-0012

SP-0013

SP-0014

Symposium REGIONAL NODAL IRRADIATION FOR BREAST CANCER 08:45 - 10:00 | AUDITORIUM

The first speaker in this session will review conflicting data around surgical and radiotherapeutic man- agement of the axilla in breast cancer patients and how these impact on current clinical practice. The second speaker will review recently published data on irradiation of the internal mammary chain (IMC) with a view to determining whether every node-positive patient should have the IMC irradiated. The final talk will cover technical approaches to treating locoregional lymph nodes and will review the evidence base for dose constraints, the dosimetric consequences of different technical approaches including protons, and the resource impact on our departments. Chair: A. Kirby (UK) Co-Chair: R. Orecchia (Italy)

INTERDISCIPLINARY RADIOBIOLOGY

CLINICAL BRACHYTHERAPY PHYSICS

RTT

YOUNG

SCIENTIFIC PROGRAMME | PROGRAMME AND EXHIBITION GUIDE

60